N/A N=209 Flexiva Pulse Registry
Urinary Calculi · Benign Prostatic Hyperplasia
Primary: Occurrence of Serious Adverse Device Effects - Primary Safety Endpoint — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Phase 2 N=25 Adoptive Cell Therapy Across Cancer Diagnoses
Cancer
Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants
Phase 2 N=343 Improving Self-care of Heart Failure Caregivers
Heart Failure
Primary: Change in the Health Self-Care Neglect (HSCN) Scale — 4.89; 4.97; 3.09; 3.50 score on a scale — p=0.04
N/A N=56 Validity and Feasibility of the CRSR-FAST
Disorder of Consciousness · Traumatic Brain Injury
Primary: Diagnostic Agreement — .68 Simple Kappa (SE)
N/A N=3,015,000 Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
Pulmonary Disease, Chronic Obstructive
Primary: Number of Hospital Admissions in Chronic Obstructive Pulmonary Disease (COPD) Patients — 665; 765 Hospitalizations — p=0.24
N/A N=9,652 Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With Treatment-related Adverse Events or Serious Treatment-related Adverse Events in Participants Who Received XELJANZ — 41.60; 12.88…
N/A N=40 Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: COPD Event — 28 Participants
N/A N=10 Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
Acne Scars - Mixed Atrophic and Hypertrophic · Acne
Primary: Subject Acne Severity Scale — 0; 1; 2; 7 Participants
N/A N=50 Interactive Obesity Treatment Approach for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI
Obesity · Overweight · Severe Mental Disorder
Primary: Body Mass Index — 43.1; 38.1; 40.3; 40.3 kg/m^2 — p=0.97
Phase 3 N=167 Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
Knee Osteoarthritis · Pain Management
Primary: NRS Scores Through 96 Hours Post-surgery — 594.4; 650.1 units on a scale*hours — p=0.0074
Phase 3 N=58,747 Azithromycin-Prevention in Labor Use Study (A-PLUS)
Maternal Death · Maternal Infections Affecting Fetus or Newborn · Neonatal SEPSIS
Primary: Maternal Death or Sepsis Within 6 Weeks (42 Days) Post-delivery in Intervention vs. Placebo Group. — 227; 344 Participants — p=<0.001
Phase 1 N=109 A Study of PF-07258669 In Healthy Adult Participants
Healthy Participants
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 6 Participants
N/A N=2,554 Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
Papillomavirus Vaccines
Primary: Human Papillomavirus or HPV-vaccine-dose Receipt — 782; 578; 408; 1056 Participants
N/A N=240 Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)
Osteoarthritis
Primary: Change From Baseline to Month 6 in Objectively Assessed Physical Activity (Accelerometer) — -2.40; -10.8 Minutes per week — p=0.3086